EUCTR2009-012451-18-NL进行中（未招募）不适用
EUROACTION PLUS: Intensive smoking intervention (Varenicline) during a preventive cardiology programme for patients with established atherosclerotic disease, people at high cariovascular risk and their families - EUROACTION PLUS INTENSIVE SMOKING INTERVENTION (VARENICLINE)
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,060
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 Vascular patients and partners
- •All patients, men and women 18 years of age or older but less than 80 years, with a new or recurrent diagnosis of coronary or other atherosclerotic vascular disease, and who are continuing to smoke, will be eligible for the programme.
- •Patients may fulfill more than one of thefollowing criteria:
- •1) Acute myocardial infarction (STEMI or NSTEMI)
- •2) Unstable angina
- •3) Stable angina pectoris
- •4) Elective revascularisation:
- •- coronary artery by-pass graft (CABG)
- •- percutaneus transluminal angioplasty (PTCA)
- •6)Transient iscaemic attack (TIA)
- •7)Peripheral vascular disease (PVD)
- •The partners of all recruited vascular patients will also be identified and invited to participate in the programme.
- •2. High-risk patients and partners
- •All high risk people who meet the following inclusion criteria: Men and women, 50 years of age or older, but less than 80 years, who are smokers and either
- •1) are newly identified high multifactorial risk individuals: CVD risk equal or greater than 5% over 10 years (now or projected to age 60 years), according to the HeartScore risk estimation system; or
- •2) have been treated with antihypertensive and/or lipid-lowering therapies in the last year; or
- •3) have diabetes mellitus diagnosed within the last 3 years.
- •The partners of all recruited high risk patients will also be identified and invited to participate in the programme.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Vascular patients:
- •- severe heart failure
- •- severe physical disability
- •- impaired cognitive function
- •- patients with acute coronary syndromes, with or without revasularisation, will not be included in the study until 2 weeks has elapsed following their coronary event.
- •High risk people:
- •- history of coronary heart disease
- •- severe heart failure
- •- severe physical disability
- •- impaired cognitive function
研究者
相似试验
进行中（未招募）
不适用
EUROACTION PLUS: Intensive smoking intervention (Varenicline) during a preventive cardiology programme for patients with established atherosclerotic disease, people at high cariovascular risk and their families - EUROACTION PLUS INTENSIVE SMOKING INTERVENTION (VARENICLINE)Current cigarette smokers with coronary or other atherosclerotic disease or people at high risk of developing cardiovascular diseaseLevel: LLTClassification code 10053325Term: Smoking cessation therapyEUCTR2009-012451-18-GBImperial College London1,060
已完成
不适用
EUROACTION PLUS intensive smoking intervention (varenicline)ISRCTN22073647Imperial College London (UK)1,060
已完成
4 期
Euroaction plus intensive smoking intervention (varenicline)prevention of cardiovascular diseasesmoking cessation1008220610003216NL-OMON38232Clinical Research Governance Office,Sir Alexander Fleming Building, Imperial College212
进行中（未招募）
1 期
EUROACTION PLUS con intervención intensiva sobre el tabaco (vareniclina) durante un programa de cardiología preventiva para pacientes con enfermedad aterosclerosa establecida, individuos con alto riesgo cardiovascular y sus familias - EUROACTION PLUS CON INTERVENCIÓN INTENSIVA SOBRE EL TABACO (VARENICLINA)Pacientes fumadores con enfermedad cardiovascular u otra enfermedad aterosclerosa o individuos con riesgo elevado de padecer ECVMedDRA version: 12.1Level: LLTClassification code 10053325Term: Smoking cessation therapyEUCTR2009-012451-18-ESImperial College London696
招募中
不适用
European action on secondary and primary prevention of coronary heart disease in order to reduce events (part III)atherosclerosisNL-OMON30196Erasmus MC, Universitair Medisch Centrum Rotterdam800